Skeletal health of children and adolescents with inflammatory bowel disease

Journal of Pediatric Gastroenterology and Nutrition

Volumn 53, Issue 1, 2011, Pages 11-25

  Pappa, Helen ^a   Thayu, Meena ^b   Sylvester, Francisco ^c   Leonard, Mary ^b   Zemel, Babette ^b   Gordon, Catherine ^a  

^a BOSTON CHILDREN S HOSPITAL   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c Division of Pediatric Infectious Diseases   (United States)

Author keywords

adolescents; children; clinical report; inflammatory bowel disease; skeletal health

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; C REACTIVE PROTEIN; CALCIUM; GLUCOCORTICOID; GROWTH HORMONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INFLIXIMAB; INTERLEUKIN 6; LEPTIN; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; SOMATOMEDIN B; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN C; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; VITAMIN D;

ADOLESCENT; ARTICLE; BODY COMPOSITION; BODY MASS; BONE BIOPSY; BONE DENSITY; BONE GROWTH; BONE MASS; BONE METABOLISM; BONE MINERALIZATION; BONE REMODELING; CALCIUM BALANCE; CALCIUM INTAKE; CELL DIFFERENTIATION; CHILD; CLINICAL ASSESSMENT; CLINICAL EVALUATION; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORTICOSTEROID THERAPY; CROHN DISEASE; CYTOKINE PRODUCTION; DELAYED PUBERTY; DIETARY INTAKE; DUAL ENERGY X RAY ABSORPTIOMETRY; ENTERITIS; EXERCISE; GROWTH CURVE; GROWTH RETARDATION; HEALTH STATUS; HEIGHT; HOMEOSTASIS; HUMAN; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; INFLAMMATION; MALABSORPTION; MALNUTRITION; MENSTRUAL IRREGULARITY; MORBIDITY; MUSCLE MASS; NUTRITIONAL ASSESSMENT; NUTRITIONAL SUPPORT; OSSIFICATION; OSTEOBLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT MONITORING; PHYSICAL ACTIVITY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PUBERTY; RISK ASSESSMENT; SCREENING; SKELETAL HEALTH; T LYMPHOCYTE ACTIVATION; VERTEBRA FRACTURE; VITAMIN DEFICIENCY; VITAMIN SUPPLEMENTATION;

ADOLESCENT; ADULT; AGE FACTORS; ANIMALS; BONE DISEASES; CHILD; CHILD DEVELOPMENT; EVIDENCE-BASED MEDICINE; HUMANS; INFLAMMATORY BOWEL DISEASES; NUTRITIONAL STATUS; RISK FACTORS;

EID: 79959817514     PISSN: 02772116     EISSN: 15364801     Source Type: Journal    
DOI: 10.1097/MPG.0b013e31821988a3     Document Type: Article

References (170)

1. Frost HM. Bone mass and the mechanostat: a proposal. Anat Rec 1987;219:1-9.
2. Suda T, Udagawa N, Nakamura I, et al. Modulation of osteoclast differentiation by local factors. Bone 1995;17(2 suppl):87S-91S.
3. Lo Celso C, Fleming HE, Wu JW, et al. Live-animal tracking of individual haematopoietic stem/progenitor cells in their niche. Nature 2009;457:92-6.
4. Takahashi N, Udagawa N, Suda T. A new member of tumor necrosis factor ligand family, ODF/OPGL/TRANCE/RANKL, regulates osteoclast differentiation and function. Biochem Biophys Res Commun 1999;256:449-55. (Pubitemid 29301126)
5. Yasuda H, Shima N, Nakagawa N, et al. Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. Proc Natl Acad Sci U S A 1998;95:3597-602.
6. Osteoporosis Prevention, Diagnosis, and Therapy. NIH Consensus Statement. Bethesda, MD: National Institutes of Health; 2000.
7. Canalis E. The fate of circulating osteoblasts. N Engl J Med 2005;352:2014-6. (Pubitemid 40638373)
8. Leonard MB. Glucocorticoid-induced osteoporosis in children: impact of the underlying disease. Pediatrics 2007;119 (suppl 2): S166-74. (Pubitemid 46397939)
9. Pfefferkorn M, Burke G, Griffiths A, et al. Growth abnormalities persist in newly diagnosed children with Crohn disease despite current treatment paradigms. J Pediatr Gastroenterol Nutr 2009;48:168-74.
10. Sylvester FA, Wyzga N, Hyams JS, et al. Natural history of bone metabolism and bone mineral density in children with inflammatory bowel disease. Inflamm Bowel Dis 2007;13:42-50. (Pubitemid 46080008)
11. Ward LM, Rauch F, Matzinger MA, et al. Iliac bone histomorphometry in children with newly diagnosed inflammatory bowel disease. Osteoporos Int 2010;21:331-7.
12. Dubner SE, Shults J, Baldassano RN, et al. Longitudinal assessment of bone density and structure in an incident cohort of children with Crohn's disease. Gastroenterology 2009;136:123-30.
13. Sylvester FA, Leopold S, Lincoln M, et al. A two-year longitudinal study of persistent lean tissue deficits in children with Crohn's disease. Clin Gastroenterol Hepatol 2009;7:452-5.
14. Thayu M, Denson LA, Shults J, et al. Determinants of changes in linear growth and body composition in incident pediatric Crohn's disease. Gastroenterology 2010;139:430-8.
15. Varghese S, Wyzga N, Griffiths AM, et al. Effects of serum from children with newly diagnosed Crohn disease on primary cultures of rat osteoblasts. J Pediatr Gastroenterol Nutr 2002;35:641-8. (Pubitemid 35417735)
16. Sylvester FA, Davis PM, Wyzga N, et al. Are activated T cells regulators of bone metabolism in children with Crohn disease? J Pediatr 2006;148:461-6.
17. Moschen AR, Kaser A, Enrich B, et al. The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. Gut 2005;54:479-87.
18. Thayu M, Leonard MB, Hyams JS, et al. Improvement in biomarkers of bone formation during infliximab therapy in pediatric Crohn's disease: results of the REACH study. Clin Gastroenterol Hepatol 2008;6:1378-84.
19. Walters TD, Gilman AR, Griffiths AM. Linear growth improves during infliximab therapy in children with chronically active severe Crohn's disease. Inflamm Bowel Dis 2007;13:424-30. (Pubitemid 46668247)
20. Bischoff SC, Herrmann A, Goke M, et al. Altered bone metabolism in inflammatory bowel disease. Am J Gastroenterol 1997;92:1157-63. (Pubitemid 27304813)
21. Pollak RD, Karmeli F, Eliakim R, et al. Femoral neck osteopenia in patients with inflammatory bowel disease. Am J Gastroenterol 1998;93:1483-90. (Pubitemid 29075187)
22. Burnham JM, Shults J, Semeao E, et al. Whole body BMC in pediatric Crohn disease: independent effects of altered growth, maturation, and body composition. J Bone Miner Res 2004;19:1961-8. (Pubitemid 41103410)
23. Gokhale R, Favus MJ, Karrison T, et al. Bone mineral density assessment in children with inflammatory bowel disease. Gastroenterology 1998;114:902-11. (Pubitemid 28217555)
24. Harpavat M, Greenspan SL, O'Brien C, et al. Altered bone mass in children at diagnosis of Crohn disease: a pilot study. J Pediatr Gastroenterol Nutr 2005;40:295-300. (Pubitemid 40344094)
25. Bonjour JP, Theintz G, Buchs B, et al. Critical years and stages of puberty for spinal and femoral bone mass accumulation during adolescence. J Clin Endocrinol Metab 1991;73:555-63. (Pubitemid 21921908)
26. Theintz G, Buchs B, Rizzoli R, et al. Longitudinal monitoring of bone mass accumulation in healthy adolescents: evidence for a marked reduction after 16 years of age at the levels of lumbar spine and femoral neck in female subjects. J Clin Endocrinol Metab 1992;75:1060-5.
27. Heyman MB, Kirschner BS, Gold BD, et al. Children with early-onset inflammatory bowel disease (IBD): analysis of a pediatric IBD consortium registry. J Pediatr 2005;146:35-40. (Pubitemid 40091728)
28. Clark EM, Ness AR, Bishop NJ, et al. Association between bone mass and fractures in children: a prospective cohort study. J Bone Miner Res 2006;21:1489-95. (Pubitemid 44300056)
29. Persad R, Jaffer I, Issenman RM. The prevalence of long bone fractures in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2006;43:597-602. (Pubitemid 44863684)
30. Kappelman MD, Bousvaros A. Nutritional concerns in pediatric inflammatory bowel disease patients. Mol Nutr Food Res 2008; 52:867-74.
31. Burnham JM, Shults J, Weinstein R, et al. Childhood onset arthritis is associated with an increased risk of fracture: a population based study using the General Practice Research Database. Ann Rheum Dis 2006;65:1074-9. (Pubitemid 44133272)
32. Francis RM, Baillie SP, Chuck AJ, et al. Acute and long-term management of patients with vertebral fractures. QJM 2004;97:63-74. (Pubitemid 38219804)
33. Siffledeen JS, Siminoski K, Jen H, et al. Vertebral fractures and role of low bone mineral density in Crohn's disease. Clin Gastroenterol Hepatol 2007;5:721-8. (Pubitemid 46830056)
34. Klaus J, Armbrecht G, Steinkamp M, et al. High prevalence of osteoporotic vertebral fractures in patients with Crohn's disease. Gut 2002;51:654-8. (Pubitemid 35216851)
35. Heijckmann AC, Huijberts MS, Schoon EJ, et al. High prevalence of morphometric vertebral deformities in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 2008;20:740-7.
36. Semeao EJ, Stallings VA, Peck SN, et al. Vertebral compression fractures in pediatric patients with Crohn's disease. Gastroenterology 1997;112:1710-3. (Pubitemid 27181398)
37. Lucarelli S, Borrelli O, Paganelli M, et al. Vertebral fractures and increased sensitivity to corticosteroids in a child with ulcerative colitis: successful use of pamidronate. J Pediatr Gastroenterol Nutr 2006; 43:533-5. (Pubitemid 44569016)
38. Baxter-Jones AD, McKay H, Burrows M, et al. International longitudinal pediatric reference standards for bone mineral content. Bone 2010;46:208-16.
39. Boot AM, Bouquet J, Krenning EP, et al. Bone mineral density and nutritional status in children with chronic inflammatory bowel disease. Gut 1998;42:188-94. (Pubitemid 28214002)
40. Lopes LH, Sdepanian VL, Szejnfeld VL, et al. Risk factors for low bone mineral density in children and adolescents with inflammatory bowel disease. Dig Dis Sci 2008;53:2746-53.
41. Semeao EJ, Jawad AF, Zemel BS, et al. Bone mineral density in children and young adults with Crohn's disease. Inflamm Bowel Dis 1999;5:161-6.
42. Bikle DD. Growth hormone/insulin-like growth factor-1/PTH axis in bone. J Bone Miner Res 2008;23:581-3. (Pubitemid 351575012)
43. Brixen K, Nielsen HK, Mosekilde L, et al. A short course of recombinant human growth hormone treatment stimulates osteoblasts and activates bone remodeling in normal human volunteers. J Bone Miner Res 1990;5:609-18. (Pubitemid 20237560)
44. Saggese G, Baroncelli GI, Bertelloni S, et al. The effect of long-term growth hormone (GH) treatment on bone mineral density in children with GH deficiency. Role of GH in the attainment of peak bone mass. J Clin Endocrinol Metab 1996;81:3077-83. (Pubitemid 26323912)
45. Wang Y, Nishida S, Boudignon BM, et al. IGF-I receptor is required for the anabolic actions of parathyroid hormone on bone. J Bone Miner Res 2007;22:1329-37. (Pubitemid 351339678)
46. Schiessl H, Frost HM, Jee WS. Estrogen and bone-muscle strength and mass relationships. Bone 1998;22:1-6. (Pubitemid 28033646)
47. Bechtold S, Alberer M, Arenz T, et al. Reduced muscle mass and bone size in pediatric patients with inflammatory bowel disease. Inflamm Bowel Dis 2010;16:216-25.
48. Paganelli M, Albanese C, Borrelli O, et al. Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. Inflamm Bowel Dis 2007;13:416-23. (Pubitemid 46668246)
49. Schmidt S, Mellstrom D, Norjavaara E, et al. Low bone mineral density in children and adolescents with inflammatory bowel disease: A population-based study from Western Sweden. Inflamm Bowel Dis 2009;15:1844-50.
50. Misra M. Long-term skeletal effects of eating disorders with onset in adolescence. Ann N Y Acad Sci 2008;1135:212-8. (Pubitemid 351862120)
51. Misra M. Bone density in the adolescent athlete. Rev Endocr Metab Disord 2008;9:139-44.
52. Frisch RE. Body weight, body fat, and ovulation. Trends Endocrinol Metab 1991;2:191-7.
53. Finkelstein JS, Neer RM, Biller BM, et al. Osteopenia in men with a history of delayed puberty. N Engl J Med 1992;326:600-4.
54. Finkelstein JS, Klibanski A, Neer RM. A longitudinal evaluation of bone mineral density in adult men with histories of delayed puberty. J Clin Endocrinol Metab 1996;81:1152-5. (Pubitemid 26083985)
55. DeBoer MD, Li Y, Cohn S. Colitis causes delay in puberty in female mice out of proportion to changes in leptin and corticosterone. J Gastroenterol 2010;45:277-84.
56. Bourges O, Dorgeret S, Alberti C, et al. Low bone mineral density in children with Crohn's disease. Arch Pediatr 2004;11:800-6. [in French]. (Pubitemid 38979794)
57. Cowan FJ, Warner JT, Dunstan FD, et al. Inflammatory bowel disease and predisposition to osteopenia. Arch Dis Child 1997;76:325-9. (Pubitemid 27174542)
58. Walther F, Fusch C, Radke M, et al. Osteoporosis in pediatric patients suffering from chronic inflammatory bowel disease with and without steroid treatment. J Pediatr Gastroenterol Nutr 2006;43:42-51. (Pubitemid 44022385)
59. Dalle Carbonare L, Bertoldo F, Valenti MT, et al. Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 2005; 36:645-52. (Pubitemid 41745029)
60. O'Brien CA, Jia D, Plotkin LI, et al. Glucocorticoids act directly on osteoblasts and osteocytes to induce their apoptosis and reduce bone formation and strength. Endocrinology 2004;145:1835-41. (Pubitemid 38402392)
61. Patschan D, Loddenkemper K, Buttgereit F. Molecular mechanisms of glucocorticoid-induced osteoporosis. Bone 2001;29:498-505. (Pubitemid 33124290)
62. Morris HA, Need AG, O'Loughlin PD, et al. Malabsorption of calcium in corticosteroid-induced osteoporosis. Calcif Tissue Int 1990;46:305-8. (Pubitemid 20161771)
63. Suzuki Y, Ichikawa Y, Saito E, et al. Importance of increased urinary calcium excretion in the development of secondary hyperparathyroidism of patients under glucocorticoid therapy. Metabolism 1983; 32:151-6. (Pubitemid 13194649)
64. Vihinen MK, Kolho KL, Ashorn M, et al. Bone turnover and metabolism in paediatric patients with inflammatory bowel disease treated with systemic glucocorticoids. Eur J Endocrinol 2008;159:693-8.
65. Ward LM. Osteoporosis due to glucocorticoid use in children with chronic illness. Horm Res 2005;64:209-21. (Pubitemid 41636325)
66. Walsh NC, Crotti TN, Goldring SR, et al. Rheumatic diseases: the effects of inflammation on bone. Immunol Rev 2005;208:228-51. (Pubitemid 41746396)
67. Uno JK, Kolek OI, Hines ER, et al. The role of tumor necrosis factor alpha in down-regulation of osteoblast Phex gene expression in experimental murine colitis. Gastroenterology 2006;131:497-509. (Pubitemid 44142455)
68. Gilbert LC, Rubin J, Nanes MS. The p55 TNF receptor mediates TNF inhibition of osteoblast differentiation independently of apoptosis. Am J Physiol Endocrinol Metab 2005;288:E1011-8. (Pubitemid 40547896)
69. Abu-Amer Y, Ross FP, Edwards J, et al. Lipopolysaccharide-stimulated osteoclastogenesis is mediated by tumor necrosis factor via its P55 receptor. J Clin Invest 1997;100:1557-65. (Pubitemid 27425783)
70. Kobayashi K, Takahashi N, Jimi E, et al. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 2000; 191:275-86.
71. Zhang YH, Heulsmann A, Tondravi MM, et al. Tumor necrosis factoralpha (TNF) stimulates RANKL-induced osteoclastogenesis via coupling of TNF type 1 receptor and RANK signaling pathways. J Biol Chem 2001;276:563-8. (Pubitemid 32050352)
72. De Benedetti F, Rucci N, Del Fattore A, et al. Impaired skeletal development in interleukin-6-transgenic mice: a model for the impact of chronic inflammation on the growing skeletal system. Arthritis Rheum 2006;54:3551-63. (Pubitemid 44737167)
73. Itoh S, Udagawa N, Takahashi N, et al. A critical role for interleukin-6 family-mediated Stat3 activation in osteoblast differentiation and bone formation. Bone 2006;39:505-12. (Pubitemid 44149269)
74. Sylvester FA, Wyzga N, Hyams JS, et al. Effect of Crohn's disease on bone metabolism in vitro: a role for interleukin-6. J Bone Miner Res 2002;17:695-702. (Pubitemid 34246645)
75. Jilka RL, Hangoc G, Girasole G, et al. Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 1992; 257:88-91.
76. Liu XH, Kirschenbaum A, Yao S, et al. Cross-talk between the interleukin-6 and prostaglandin E(2) signaling systems results in enhancement of osteoclastogenesis through effects on the osteoprotegerin/ receptor activator of nuclear factor-{kappa}B (RANK) ligand/ RANK system. Endocrinology 2005;146:1991-8. (Pubitemid 40396909)
77. Romas E, Gillespie MT, Martin TJ. Involvement of receptor activator of NFkappaB ligand and tumor necrosis factor-alpha in bone destruction in rheumatoid arthritis. Bone 2002;30:340-6. (Pubitemid 34154863)
78. Siggelkow H, Eidner T, Lehmann G, et al. Cytokines, osteoprotegerin, and RANKL in vitro and histomorphometric indices of bone turnover in patients with different bone diseases. J Bone Miner Res 2003; 18:529-38. (Pubitemid 36241070)
79. Gafni RI, Baron J. Overdiagnosis of osteoporosis in children due to misinterpretation of dual-energy x-ray absorptiometry (DEXA). J Pediatr 2004;144:253-7. (Pubitemid 38869404)
80. Kalkwarf HJ, Zemel BS, Gilsanz V, et al. The bone mineral density in childhood study: bone mineral content and density according to age, sex, and race. J Clin Endocrinol Metab 2007; 92:2087-99. (Pubitemid 46997105)
81. Wren TA, Liu X, Pitukcheewanont P, et al. Bone densitometry in pediatric populations: discrepancies in the diagnosis of osteoporosis by DXA and CT. J Pediatr 2005;146:776-9. (Pubitemid 40840598)
82. Gordon CM, Bachrach LK, Carpenter TO, et al. Dual energy X-ray absorptiometry interpretation and reporting in children and adolescents: the 2007 ISCD Pediatric Official Positions. J Clin Densitom 2008;11:43-58. (Pubitemid 351602187)
83. Zemel B, Leonard, MB, Kelly, A, et al. Adjustment for height in the clinical assessment of DXA measures of bone mass and density in children. J Clin Endocrinol Metab 2010;95:1265-73.
84. PepplerWW, Mazess RB. Total body bone mineral and lean body mass by dual-photon absorptiometry. I. Theory and measurement procedure. Calcif Tissue Int 1981;33:353-9. (Pubitemid 12249944)
85. Burnham JM, Shults J, Semeao E, et al. Body-composition alterations consistent with cachexia in children and young adults with Crohn disease. Am J Clin Nutr 2005;82:413-20.
86. Parfitt AM. The two faces of growth: benefits and risks to bone integrity. Osteoporos Int 1994;4:382-98.
87. Kelly TL, Wilson KE, Heymsfield SB. Dual energy X-ray absorptiometry body composition reference values from NHANES. PLoS One 2009;4:e7038.
88. Crabtree NJ, Kibirige MS, Fordham JN, et al. The relationship between lean body mass and bone mineral content in paediatric health and disease. Bone 2004;35:965-72. (Pubitemid 39349228)
89. Lewiecki EM, Gordon CM, Baim S, et al. International Society for Clinical Densitometry 2007 adult and pediatric official positions. Bone 2008;43:1115-21.
90. Rauch F, Plotkin H, DiMeglio L, et al. Fracture prediction and the definition of osteoporosis in children and adolescents: the ISCD 2007 Pediatric Official Positions. J Clin Densitom 2008;11:22-8. (Pubitemid 351602185)
91. Schousboe JT, Vokes T, Broy SB, et al. Vertebral fracture assessment: the 2007 ISCD Official Positions. J Clin Densitom 2008;11:92-108. (Pubitemid 351602190)
92. Tanner JM, Goldstein H, Whitehouse RH. Standards for children's height at ages 2-9 years allowing for heights of parents. Arch Dis Child 1970;45:755-62.
93. Luo ZC, Albertsson-Wikland K, Karlberg J. Target height as predicted by parental heights in a population-based study. Pediatr Res 1998; 44:563-71. (Pubitemid 28447344)
94. Carswell JSD. Normal physical growth and development. In: Neinstein LS, Gordon C, Katzman D, et al, eds. Adolescent Health Care: A Practical Guide. Philadelphia: Lippincott Williams & Wilkins; 2008.
95. Rogol AD, Clark PA, Roemmich JN. Growth and pubertal development in children and adolescents: effects of diet and physical activity. Am J Clin Nutr 2000;72(2 suppl):521S-8S. (Pubitemid 30650050)
96. Adams Hillard PJ. Menstruation in adolescents: what's normal, what's not. Ann N Y Acad Sci 2008;1135:29-35. (Pubitemid 351863669)
97. Holick MF. Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80(6 suppl):1678S-88S.
98. Bouillon R, Okamura WH, Norman AW. Structure-function relationships in the vitamin D endocrine system. Endocr Rev 1995;16:200-57.
99. Haddad JG. Plasma vitamin D-binding protein (Gc-globulin): multiple tasks. J Steroid Biochem Mol Biol 1995;53:579-82.
100. Christakos S, Dhawan P, Liu Y, et al. New insights into the mechanisms of vitamin D action. J Cell Biochem 2003;88:695-705. (Pubitemid 36258819)
101. DeLuca HF. Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80(6 suppl):1689S-96S.
102. Panda DK, Miao D, Bolivar I, et al. Inactivation of the 25-hydroxyvitamin D 1alpha-hydroxylase and vitamin D receptor demonstrates independent and interdependent effects of calcium and vitamin D on skeletal and mineral homeostasis. J Biol Chem 2004; 279:16754-66. (Pubitemid 38509378)
103. Atkins GJ, Kostakis P, Pan B, et al. RANKL expression is related to the differentiation state of human osteoblasts. J Bone Miner Res 2003; 18:1088-98. (Pubitemid 37294947)
104. Rickard DJ, Kazhdan I, Leboy PS. Importance of 1,25-dihydroxyvitamin D3 and the nonadherent cells of marrow for osteoblast differentiation from rat marrow stromal cells. Bone 1995;16:671-8.
105. Medhora MM, Teitelbaum S, Chappel J, et al. 1 alpha,25-dihydroxyvitamin D3 up-regulates expression of the osteoclast integrin alpha v beta 3. J Biol Chem 1993;268:1456-61. (Pubitemid 23019798)
106. Mimura H, Cao X, Ross FP, et al. 1,25-Dihydroxyvitamin D3 transcriptionally activates the beta 3-integrin subunit gene in avian osteoclast precursors. Endocrinology 1994;134:1061-6.
107. Tuchman S, Thayu M, Shults J, et al. Interpretation of biomarkers of bone metabolismin children: impact of growth velocity and body size in healthy children and chronic disease. J Pediatr 2008;153:484-90.
108. Pappa HM, Gordon CM, Saslowsky TM, et al. Vitamin D status in children and young adults with inflammatory bowel disease. Pediatrics 2006;118:1950-61. (Pubitemid 46393676)
109. Lamberg-Allardt CJ, Viljakainen HT. 25-Hydroxyvitamin D and functional outcomes in adolescents. Am J Clin Nutr 2008;88:534S-6S.
110. Leslie WD, Miller N, Rogala L, et al. Vitamin D status and bone density in recently diagnosed inflammatory bowel disease: the Manitoba IBD Cohort Study. Am J Gastroenterol 2008;103:1451-9. (Pubitemid 351813899)
111. Chapuy MC, Preziosi P, Maamer M, et al. Prevalence of vitamin D insufficiency in an adult normal population. Osteoporos Int 1997; 7:439-43. (Pubitemid 27443069)
112. Heaney RP, Dowell MS, Hale CA, et al. Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am Coll Nutr 2003;22:142-6. (Pubitemid 36417827)
113. Malabanan A, Veronikis IE, Holick MF. Redefining vitamin D insufficiency. Lancet 1998;351:805-6. (Pubitemid 28112350)
114. Tangpricha V, Pearce EN, Chen TC, et al. Vitamin D insufficiency among free-living healthy young adults. Am J Med 2002;112:659-62. (Pubitemid 34597167)
115. Aris RM, Merkel PA, Bachrach LK, et al. Guide to bone health and disease in cystic fibrosis. J Clin Endocrinol Metab 2005;90:1888-96. (Pubitemid 40464064)
116. Sentongo TA, Semaeo EJ, Stettler N, et al. Vitamin D status in children, adolescents, and young adults with Crohn disease. Am J Clin Nutr 2002;76:1077-81. (Pubitemid 35244680)
117. El-MataryW, Sikora S, Spady D. Bone mineral density, vitamin D, and disease activity in children newly diagnosed with inflammatory bowel disease. Dig Dis Sci 2011;56:825-9.
118. Webb AR, Kline L, Holick MF. Influence of season and latitude on the cutaneous synthesis of vitamin D3: exposure to winter sunlight in Boston and Edmonton will not promote vitamin D3 synthesis in human skin. J Clin Endocrinol Metab 1988;67:373-8.
119. Misra M, Pacaud D, Petryk A, et al. Vitamin D deficiency in children and its management: review of current knowledge and recommendations. Pediatrics 2008;122:398-417.
120. Wagner CL, Greer FR. Prevention of rickets and vitamin D deficiency in infants, children, and adolescents. Pediatrics 2008;122:1142-52.
121. Armas LA, Hollis BW, Heaney RP. Vitamin D2 is much less effective than vitamin D3 in humans. J Clin Endocrinol Metab 2004;89:5387-91. (Pubitemid 39518413)
122. Trang HM, Cole DE, Rubin LA, et al. Evidence that vitamin D3 increases serum 25-hydroxyvitamin D more efficiently than does vitamin D2. Am J Clin Nutr 1998;68:854-8. (Pubitemid 28471068)
123. Brasier AR, Nussbaum SR. Hungry bone syndrome: clinical and biochemical predictors of its occurrence after parathyroid surgery. Am J Med 1988;84:654-60.
124. Rovner AJ, Stallings VA, Schall JI, et al. Vitamin D insufficiency in children, adolescents, and young adults with cystic fibrosis despite routine oral supplementation. Am J Clin Nutr 2007;86:1694-9. (Pubitemid 350232185)
125. Alaimo K, McDowell MA, Briefel RR, et al. Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-1891. Adv Data 1994(258):1-28.
126. Cavadini C, Siega-Riz AM, Popkin BM. US adolescent food intake trends from 1965 to 1996. Arch Dis Child 2000;83:18-24. (Pubitemid 30460134)
127. Bonjour JP, Carrie AL, Ferrari S, et al. Calcium-enriched foods and bone mass growth in prepubertal girls: a randomized, double-blind, placebo-controlled trial. J Clin Invest 1997;99:1287-94. (Pubitemid 27142766)
128. Lloyd T, Andon MB, Rollings N, et al. Calcium supplementation and bone mineral density in adolescent girls. JAMA 1993;270:841-4. (Pubitemid 23234112)
129. Lloyd T, Martel JK, Rollings N, et al. The effect of calcium supplementation and Tanner stage on bone density, content and area in teenage women. Osteoporos Int 1996;6:276-83. (Pubitemid 26280820)
130. Johnston CC Jr, Miller JZ, SlemendaCW, et al. Calcium supplementation and increases in bone mineral density in children. N Engl J Med 1992;327:82-7.
131. Cameron MA, Paton LM, Nowson CA, et al. The effect of calcium supplementation on bone density in premenarcheal females: a co-twinapproach. J Clin Endocrinol Metab 2004;89:4916-22. (Pubitemid 39391428)
132. Iuliano-Burns S, Saxon L, Naughton G, et al. Regional specificity of exercise and calcium during skeletal growth in girls: a randomized controlled trial. J Bone Miner Res 2003;18:156-62. (Pubitemid 36008352)
133. Specker B, Binkley T. Randomized trial of physical activity and calcium supplementation on bone mineral content in 3- to 5-yearold children. J Bone Miner Res 2003;18:885-92. (Pubitemid 37294972)
134. Specker BL. Evidence for an interaction between calcium intake and physical activity on changes in bone mineral density. J Bone Miner Res 1996;11:1539-44. (Pubitemid 26331010)
135. Stauffer JQ. Hyperoxaluria intestinal disease. The role of steatorrhea and dietary calcium in regulating intestinal oxalate absorption. Am J Dig Dis 1977;22:921-8. (Pubitemid 8228682)
136. Worcester EM. Stones from bowel disease. Endocrinol Metab Clin North Am 2002;31:979-99. (Pubitemid 35403493)
137. Kelly PJ, Eisman JA, Sambrook PN. Interaction of genetic and environmental influences on peak bone density. Osteoporos Int 1990;1:56-60.
138. Mazziotti G, Angeli A, Bilezikian JP, et al. Glucocorticoid-induced osteoporosis: an update. Trends Endocrinol Metab 2006;17:144-9.
139. Borrelli O, Cordischi L, Cirulli M, et al. Polymeric diet alone versus corticosteroids in the treatment of active pediatric Crohn's disease: a randomized controlled open-label trial. Clin Gastroenterol Hepatol 2006;4:744-53. (Pubitemid 43825808)
140. Fell JM, Paintin M, Arnaud-Battandier F, et al. Mucosal healing and a fall in mucosal pro-inflammatory cytokine mRNA induced by a specific oral polymeric diet in paediatric Crohn's disease. Aliment Pharmacol Ther 2000;14:281-9. (Pubitemid 30145315)
141. Newby EA, Sawczenko A, Thomas AG, et al. Interventions for growth failure in childhood Crohn's disease. Cochrane Database Syst Rev 2005;3:CD003873.
142. Azcue M, Rashid M, Griffiths A, et al. Energy expenditure and body composition in children with Crohn's disease: effect of enteral nutrition and treatment with prednisolone. Gut 1997;41:203-8. (Pubitemid 27395923)
143. Whitten KE, Leach ST, Bohane TD, et al. Effect of exclusive enteral nutrition on bone turnover in children with Crohn's disease. J Gastroenterol 2010;45:399-405.
144. Polk DB, Hattner JA, Kerner JA Jr. Improved growth and disease activity after intermittent administration of a defined formula diet in children with Crohn's disease. JPEN J Parenter Enteral Nutr 1992; 16:499-504.
145. Belli DC, Seidman E, Bouthillier L, et al. Chronic intermittent elemental diet improves growth failure in children with Crohn's disease. Gastroenterology 1988;94:603-10. (Pubitemid 18073519)
146. Cosgrove M, Jenkins HR. Experience of percutaneous endoscopic gastrostomy in children with Crohn's disease. Arch Dis Child 1997;76:141-3. (Pubitemid 27086884)
147. Wilschanski M, Sherman P, Pencharz P, et al. Supplementary enteral nutrition maintains remission in paediatric Crohn's disease. Gut 1996;38:543-8. (Pubitemid 26111374)
148. Ali O, Shim M, Fowler E, et al. Spinal bone mineral density, IGF-1 and IGFBP-3 in children with cerebral palsy. Horm Res 2007;68:316-20. (Pubitemid 350059707)
149. Simon D, Lucidarme N, Prieur AM, et al. Effects on growth and body composition of growth hormone treatment in children with juvenile idiopathic arthritis requiring steroid therapy. J Rheumatol 2003; 30:2492-9. (Pubitemid 37413913)
150. Janz KF. Validation of the CSA accelerometer for assessing children's physical activity. Med Sci Sports Exerc 1994;26:369-75. (Pubitemid 24088803)
151. Bass S, Pearce G, Bradney M, et al. Exercise before puberty may confer residual benefits in bone density in adulthood: studies in active prepubertal and retired female gymnasts. J Bone Miner Res 1998; 13:500-7. (Pubitemid 28146233)
152. Bass SL, Saxon L, Daly RM, et al. The effect of mechanical loading on the size and shape of bone in pre-, peri-, and postpubertal girls: a study in tennis players. J Bone Miner Res 2002;17:2274-80. (Pubitemid 35416762)
153. Bass S, Pearce G, Young N, et al. Bone mass during growth: the effects of exercise. Exercise and mineral accrual. Acta Univ Carol Med (Praha) 1994;40:3-6.
154. Lloyd T, Petit MA, Lin HM, et al. Lifestyle factors and the development of bone mass and bone strength in young women. J Pediatr 2004;144:776-82. (Pubitemid 38858096)
155. Lloyd T, Chinchilli VM, Johnson-Rollings N, et al. Adult female hip bone density reflects teenage sports-exercise patterns but not teenage calcium intake. Pediatrics 2000;106(1 Pt 1):40-4. (Pubitemid 30436870)
156. Robinson RJ, Krzywicki T, Almond L, et al. Effect of a low-impact exercise program on bone mineral density in Crohn's disease: a randomized controlled trial. Gastroenterology 1998;115:36-41. (Pubitemid 28307285)
157. Gilbert L, He X, Farmer P, et al. Inhibition of osteoblast differentiation by tumor necrosis factor-alpha. Endocrinology 2000;141:3956-64.
158. Guttridge DC, Mayo MW, Madrid LV, et al. NF-kappaB-induced loss of MyoD messenger RNA: possible role in muscle decay and cachexia. Science 2000;289:2363-6.
159. Kwan Tat S, Padrines M, Theoleyre S, et al. IL-6, RANKL, TNF-alpha/ IL-1: interrelations in bone resorption pathophysiology. Cytokine Growth Factor Rev 2004;15:49-60.
160. Ryan BM, Russel MG, Schurgers L, et al. Effect of antitumour necrosis factor-alpha therapy on bone turnover in patients with active Crohn's disease: a prospective study. Aliment Pharmacol Ther 2004;20:851-7. (Pubitemid 39424892)
161. Miheller P, Muzes G, Racz K, et al. Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. Inflamm Bowel Dis 2007;13:1379-84. (Pubitemid 350206849)
162. Franchimont N, Putzeys V, Collette J, et al. Rapid improvement of bone metabolism after infliximab treatment in Crohn's disease. Aliment Pharmacol Ther 2004;20:607-14. (Pubitemid 39279048)
163. Abreu MT, Geller JL, Vasiliauskas EA, et al. Treatment with infliximab is associated with increased markers of bone formation in patients with Crohn's disease. J Clin Gastroenterol 2006;40:55-63. (Pubitemid 44378078)
164. Thayu M, Shults J, Burnham JM, et al. Gender differences in body composition deficits at diagnosis in children and adolescents with Crohn's disease. Inflamm Bowel Dis 2007;13:1121-8. (Pubitemid 47402596)
165. Bernstein M, Irwin S, Greenberg GR. Maintenance infliximab treatment is associated with improved bone mineral density in Crohn's disease. Am J Gastroenterol 2005;100:2031-5.
166. Fisher JE, Rogers MJ, Halasy JM, et al. Alendronate mechanism of action: geranylgeraniol, an intermediate in the mevalonate pathway, prevents inhibition of osteoclast formation, bone resorption, and kinase activation in vitro. Proc Natl Acad Sci U S A 1999;96:133-8. (Pubitemid 29036065)
167. Bachrach LK, Ward LM. Clinical review 1: bisphosphonate use in childhood osteoporosis. J Clin Endocrinol Metab 2009;94:400-9.
168. Phillipi CA, Remmington T, Steiner RD. Bisphosphonate therapy for osteogenesis imperfecta. Cochrane Database Syst Rev 2008;4: CD005088.
169. Thornton J, Ashcroft DM, Mughal MZ, et al. Systematic review of effectiveness of bisphosphonates in treatment of low bone mineral density and fragility fractures in juvenile idiopathic arthritis. Arch Dis Child 2006;91:753-61. (Pubitemid 44351176)
170. Ward L, Tricco AC, Phuong P, et al. Bisphosphonate therapy for children and adolescents with secondary osteoporosis. Cochrane Database Syst Rev 2007;4:CD005324.